DrugDashboards

Doxil

doxorubicin hydrochloride · DOXORUBICIN HYDROCHLORIDE 2 mg/mL · Injection, Suspension, Liposomal · Intravenous · Baxter Healthcare Company

NDC 00338-0063-01 · 1 VIAL, SINGLE-USE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-USE · NDA · View full market →

The short version

9 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$320.16
Reported to Texas DSHS · 2026 annual filing · Baxter Healthcare Corporation

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 10 MG
$116.605
HCPCS Q2050 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$11,222
24 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA050718
TE code
AB
Approval date
Nov 17, 1995
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedAug 24, 2023
    Baxter Healthcare Corporation — CGMP Deviations: Product was exposed to temperatures exceeding the labeled storage conditions during transportation were released by mistake.

Manufacturers of doxorubicin hydrochloride (Injection, Suspension, Liposomal)

LabelerStrengthFirst seenLast seen
Alembic Pharmaceuticals Inc.DOXORUBICIN HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Baxter Healthcare CompanyDOXORUBICIN HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
BluePoint LaboratoriesDOXORUBICIN HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Dr. Reddy's Laboratories Inc.DOXORUBICIN HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Lupin Pharmaceuticals, Inc.DOXORUBICIN HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
GlaxoSmithKline Manufacturing SpADOXORUBICIN HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsDOXORUBICIN HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedDOXORUBICIN HYDROCHLORIDE 2 mg/mLJul 15, 2026Aug 31, 2026
Baxter Healthcare CorporationDOXORUBICIN HYDROCHLORIDE 2 mg/mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Doxil — NDC 00338-0063-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00338006301.

Free to cite with attribution — see how the data is put together.